Nursing care
Octreotide: what to check before you give it
Written and reviewed by Dana Whitfield, RN, MSN · 3 min read · Updated September 2026
Short answer
Octreotide is a somatostatin analogue that reduces splanchnic blood flow, which is why it is the infusion of choice for bleeding oesophageal varices. It also suppresses insulin and glucagon secretion, so blood glucose can swing either way unpredictably. Monitor glucose regularly, check the infusion site, and watch for bradycardia.
Mechanism, simply
Octreotide mimics somatostatin. It switches off a wide range of secretory and vasodilatory hormones across the gut and pancreas: growth hormone, insulin, glucagon, gastrin, secretin, and vasoactive intestinal peptide.
The effect that matters most on the ward is splanchnic vasoconstriction. By cutting portal and splanchnic blood flow, octreotide lowers pressure in the varices themselves, which slows bleeding while endoscopy is arranged. The same hormone-blocking action that helps the gut also blunts the normal insulin-glucagon response, which is why glucose control on this drug is genuinely unpredictable rather than a minor footnote.
Indications you will see on the ward
The headline use is acute bleeding oesophageal or gastric varices, usually as a continuous IV infusion alongside band ligation or sclerotherapy. You will also see it for acromegaly, carcinoid tumours, and VIPomas, where it controls hormone-driven symptoms rather than bleeding.
Less commonly it is used for refractory diarrhoea in short bowel syndrome or dumping syndrome, and occasionally for pancreatic fistula output. On a general medical or GI floor, though, the variceal bleed indication is what you will be titrating and documenting against most often.
Assessment before administration
Get a baseline heart rate and blood pressure before starting, since octreotide can cause bradycardia and, less often, conduction changes on ECG in patients with existing cardiac disease. Check a baseline glucose too, and know the patient's diabetes status going in.
Confirm the indication and dose against the order: variceal bleed protocols typically run as a bolus followed by a continuous infusion measured in micrograms per hour, which is a different regimen from the subcutaneous dosing used for acromegaly or carcinoid symptoms. Review renal and hepatic function, since impaired clearance can prolong effect, and check gallbladder history, as octreotide reduces gallbladder contractility and raises the risk of gallstones with longer use.
Toxicity and the antidote
There is no specific antidote for octreotide. Management of overdose or excessive effect is supportive: stop or slow the infusion, treat bradycardia if symptomatic, and correct glucose derangement as it presents.
Watch for both hypoglycaemia and hyperglycaemia, since insulin and glucagon suppression can push glucose either direction depending on the patient. Bradyarrhythmias, QT changes, and gallbladder sludge or stones are the other toxicities to flag early rather than the ones taught as classic overdose syndromes.
Interactions that matter
Octreotide alters the absorption and metabolism of several drugs. It slows gastric emptying and gut transit, which can change the absorption timing of oral medications given alongside it, including cyclosporine.
It also reduces insulin and glucagon secretion, so insulin and oral hypoglycaemics need closer monitoring and dose adjustment while octreotide is running. Beta-blockers compound the bradycardia risk, so extra vigilance on heart rate is warranted when the two are combined.
What the patient must be told
Tell the patient their blood glucose will be checked frequently while on the infusion and that swings in either direction are expected, not a sign that something has gone wrong. If they are diabetic, explain that their usual insulin needs may change during treatment.
For patients continuing on subcutaneous octreotide after discharge, teach injection site rotation to avoid lipodystrophy and explain that pain at the injection site is common but usually settles within an hour. Mention that long-term use carries a risk of gallstones, so new right upper quadrant pain should be reported rather than ignored.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our gastrointestinal practice questions are the closest set to what this page covers.
Common questions
Why is octreotide used for variceal bleeding specifically?
It constricts the splanchnic vascular bed, which lowers portal pressure and reduces flow through the varices. This buys time for endoscopic band ligation or sclerotherapy to control the bleed directly.
Does octreotide cause high or low blood sugar?
Both are possible. Octreotide suppresses insulin and glucagon together, so the net effect on glucose depends on the individual patient, which is why frequent glucose checks are part of routine monitoring rather than an occasional add-on.
What vital sign should you watch most closely on an octreotide infusion?
Heart rate. Octreotide can cause bradycardia, and this risk increases when the patient is also on a beta-blocker, so baseline and ongoing heart rate checks matter.
Is there an antidote for octreotide toxicity?
No specific antidote exists. Treatment is supportive: slow or stop the infusion, manage bradycardia if it becomes symptomatic, and correct any glucose abnormality that develops.